In addition, to verify this hypothesis, our team is also planning to use traditional Chinese medicine, Tripterygium wilfordii Hook F, or methylation inhibitors and further develop drugs that potentially target SFRP1 to fill in the gaps related to RA-FLS therapy. The gene discussed is SFRP1; the disease is rheumatoid arthritis.